iBET

Management

Paula Alves, CEO

Paula Alves is CEO of iBET and Head of the Animal Cell Technology Unit at iBET and at the Instituto de Tecnologia Química Biológica (NOVA University of Lisbon) and Invited Associate Professor of Chemical and Biochemical Engineering at the Faculty of Sciences and Technology also at NOVA. Paula Alves has extensive experience in understanding cell metabolism to improve the efficiency of bioprocesses and at developing new tools and technologies for pre-clinical research. More recently this expertise was expanded to generate expansion and differentiation of stem cells in bioreactors. The Unit she coordinates uses Animal Cell Technology for research and development in particular for (i) production of complex biopharmaceuticals such as viral vectors, vaccines and recombinant proteins (ii) development of 3D culture systems for toxicity testing using primary cells and stem cells in bioreactors (iii) expand systems biology approaches to organize the complexity of the processes involved in the research described in (i) and (ii). She is President of the ESACT-European Society for Animal Cell Technology, Chairman of the General Assembly of the SPCE-TC, the Portuguese Society for Stem Cells and Cell Therapy and Cell Therapy and Member of the Advisory Group for Horizon 2020 Societal Challenge 1- European Commission. Paula Alves has published over 220 papers, 29 book chapters and supervised 25 PhD students.

 

Manuel Carrondo, Vice-President and founder of iBET

Manuel Carrondo is Full Professor of Chemical and Biochemical Engineering at the Faculty of Sciences and Technology, NOVA University of Lisbon. Manuel Carrondo has extensive management experience in the biotechnology sector and heads iBET’s Business Development. His key areas of interest include Animal Cell Technology and its application for human and animal health; Therapeutic and diagnostic recombinant proteins, including fusion proteins; virus like particles and pseudo viruses as vaccination agents and viruses (retro-, adeno-, lenti-) as deliverables for gene therapy; cell therapies and stem cells and cGMP pilot plant scale-up and production development of biopharmaceuticals. He is Advisory Board Member of CEVEC Pharmaceuticals, PBS Biotech, CNIC - Spanish National Center for Cardiovascular Research Carlos III, Masthercells - Manufacturing Synergies for Therapeutic Cells, Alloksys - Life Sciences BV, and IBMT - Fraunhofer Institute for Biomedical Engineering and GenIbet Biopharmaceuticals. OECD - Portuguese representative to the Working Party on Biotechnology, Nanotechnology and Converging Technologies. Manuel Carrondo has published over 230 papers and supervised 35 PhD students.